




31. (New) The thiadiazoline derivative according to claim 29, wherein the thiadiazoline derivative is represented by formula (237),



or a pharmacologically acceptable salt thereof.

32. (New) A medicament composition comprising the thiadiazoline derivative or a pharmaceutically acceptable salt thereof according to claim 29 as an active ingredient.

33. (Withdrawn - New) A medicament composition comprising the thiadiazoline derivative or a pharmaceutically acceptable salt thereof according to claim 30 as an active ingredient.

34. (New) A medicament composition comprising the thiadiazoline derivative or a pharmaceutically acceptable salt thereof according to claim 31 as an active ingredient.

35. (Withdrawn - New) A method for inhibiting a mitotic kinesin Eg5 comprising administering an effective amount of a thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 29 to inhibit the mitotic kinesin Eg5.

36. (Withdrawn - New) The method according to claim 35 wherein the thiadiazoline derivative or a pharmacologically acceptable salt thereof is administered to a human.

37. (Withdrawn - New) A method for inhibiting a mitotic kinesin Eg5 comprising administering an effective amount of a thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 30 to inhibit the mitotic kinesin Eg5.

38. (Withdrawn - New) The method according to claim 37 wherein the thiadiazoline derivative or a pharmacologically acceptable salt thereof is administered to a human.

39. (Withdrawn - New) A method for inhibiting a mitotic kinesin Eg5 comprising administering an effective amount of a thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 31 to inhibit the mitotic kinesin Eg5.

40. (Withdrawn - New) The method according to claim 39 wherein the thiadiazoline derivative or a pharmacologically acceptable salt thereof is administered to a human.